Why Is Iovance Biotherapeutics (IOVA) Down 21.2% Since Last Earnings Report?Zacks Investment Research • 09/07/23
Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 08/08/23
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung CancerGlobeNewsWire • 07/25/23
Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023GlobeNewsWire • 07/24/23
Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public OfferingGlobeNewsWire • 07/13/23
WD-40 shares climb after earnings top estimates, Iovance stock slumps on offering, and other stocks on the moveMarket Watch • 07/11/23
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common StockGlobeNewsWire • 07/11/23
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common StockGlobeNewsWire • 07/10/23
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung CancerGlobeNewsWire • 07/10/23
Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment LandscapeGlobeNewsWire • 06/20/23
Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced MelanomaGlobeNewsWire • 06/15/23
Why Is Iovance Biotherapeutics (IOVA) Up 7.9% Since Last Earnings Report?Zacks Investment Research • 06/08/23